Compare Stocks → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EQNASDAQ:IMVNASDAQ:KLDONASDAQ:STSANASDAQ:VBLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEQEquillium$2.31+12.1%$1.95$0.45▼$3.25$81.45M1.64374,253 shs386,043 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsKLDOKaleido Biosciences$0.00$0.00▼$0.03$4K-0.065,605 shs2,428 shsSTSASatsuma Pharmaceuticals$1.10-0.9%$1.08$0.59▼$8.08$36.47M0.1701,788 shs1.83 million shsVBLTVascular Biogenics$5.46-8.8%$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEQEquillium0.00%-28.47%-25.90%+202.94%+187.67%IMVIMV0.00%0.00%0.00%0.00%+69.59%KLDOKaleido Biosciences0.00%0.00%0.00%0.00%-50.00%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%+30.95%VBLTVascular Biogenics0.00%0.00%0.00%0.00%+3,111.76%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEQEquillium1.3849 of 5 stars3.52.00.00.01.91.70.0IMVIMVN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASTSASatsuma Pharmaceuticals2.7755 of 5 stars3.00.00.04.40.03.30.6VBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEQEquillium3.00Buy$3.4047.19% UpsideIMVIMV2.00HoldN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/ASTSASatsuma Pharmaceuticals2.00Hold$2.50127.27% UpsideVBLTVascular BiogenicsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEQEquillium$36.08M2.26N/AN/A$0.93 per share2.48IMVIMV$330K0.00N/AN/A($0.69) per share0.00KLDOKaleido Biosciences$1.10M0.00N/AN/AN/ANaNSTSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/AVBLTVascular Biogenics$660K642.29N/AN/A$0.32 per share17.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEQEquillium-$62.43M-$0.39N/AN/AN/A-36.96%-51.82%-22.57%5/9/2024 (Estimated)IMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/ASTSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/AVBLTVascular Biogenics-$32.30M-$0.21N/A∞N/AN/A-73.45%-54.11%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEQEquilliumN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEQEquilliumN/A1.791.91IMVIMVN/A2.932.93KLDOKaleido BiosciencesN/AN/AN/ASTSASatsuma PharmaceuticalsN/A7.447.44VBLTVascular BiogenicsN/A4.634.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEQEquillium27.05%IMVIMV15.37%KLDOKaleido Biosciences81.56%STSASatsuma Pharmaceuticals93.26%VBLTVascular Biogenics0.96%Insider OwnershipCompanyInsider OwnershipEQEquillium30.00%IMVIMV0.33%KLDOKaleido Biosciences9.00%STSASatsuma Pharmaceuticals31.20%VBLTVascular Biogenics6.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEQEquillium4535.26 million24.58 millionNot OptionableIMVIMV9711.71 million11.67 millionOptionableKLDOKaleido Biosciences7642.62 million38.79 millionNot OptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableKLDO, EQ, VBLT, STSA, and IMV HeadlinesSourceHeadlineTommy Garten elected to VBL Hall of Fametherecorderonline.com - March 28 at 1:31 PMControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemnature.com - February 21 at 3:29 PMVascular News and Researchnews-medical.net - November 25 at 2:28 PMVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26msn.com - November 3 at 12:39 AMNotable Labs Closes Merger Transaction With VBL Therapeuticsfinance.yahoo.com - October 16 at 3:55 PMVBL Therapeutics Announces Results of Annual and Special Shareholder Meetingfinance.yahoo.com - October 12 at 3:13 PMVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meetingfinance.yahoo.com - October 4 at 8:40 AMVascular Biogenics Rises on Presentation Hypefinance.yahoo.com - September 9 at 12:00 PMVBLT Stock Sees Decline of Approximately -0.22% in Last Five Daysknoxdaily.com - September 7 at 9:15 PMVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECfinance.yahoo.com - September 6 at 7:30 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 7:00 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 3:04 PMVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 14 at 8:09 AMMonitoring Vascular Biogenics Ltd. (VBLT) after recent insider movementsknoxdaily.com - July 26 at 4:10 PMVascular Biogenics (NASDAQ: VBLT)fool.com - July 23 at 5:52 PMRecent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT)knoxdaily.com - July 12 at 4:20 PMVBLT Stock Sees Decline of Approximately -4.31% in Last Five Daysknoxdaily.com - July 7 at 2:11 PMDays-to-cover ratio for VBLT surges to 0.84 due to rise in short interestknoxdaily.com - June 23 at 8:26 PMThe Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgerymedscape.com - May 18 at 1:35 AMVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 15 at 8:03 PMDeveloping a Patient-Centered Approach to Vascular Access Device Selectionmedscape.com - May 10 at 8:52 AMCADASIL: The Most Common Hereditary Subcortical Vascular Dementiamedscape.com - May 5 at 1:05 AMAspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Diseasemedscape.com - May 2 at 8:00 PMVascular Biogenics Stock (NASDAQ:VBLT), Dividendsbenzinga.com - April 4 at 1:52 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways3 wealth-compounding stocks to beat the market this decadeFebruary 28, 2024 7:00 AMView 3 wealth-compounding stocks to beat the market this decadeThis Industrial Products Stock is Goldman’s Favorite This CycleMarch 11, 2024 9:55 AMView This Industrial Products Stock is Goldman’s Favorite This Cycle3 Real Estate Stocks to Buy on Commission CutsMarch 20, 2024 6:15 AMView 3 Real Estate Stocks to Buy on Commission CutsOversold and Diverging, Chewy Stock is Ready to ReboundMarch 22, 2024 6:10 AMView Oversold and Diverging, Chewy Stock is Ready to ReboundAll Headlines Company DescriptionsEquilliumNASDAQ:EQEquillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.IMVNASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Kaleido BiosciencesNASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Satsuma PharmaceuticalsNASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Vascular BiogenicsNASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.